Sign inJoin waitlistJoin the waitlist

Thomas Samuel

Program Director · Cleveland Clinic Foundation

Credentials: · · · · ·

History

Cleveland Clinic Foundation
Present

Temple University Hospital
2002–2004
Internal Medicine
Vanderbilt University Medical Center
1998–2001
Renaissance School of Medicine at Stony Brook University
1994–1998
Swarthmore College
1990–1994

Research

First-in-human phase I dose-escalation study of the HSP90 inhibitor AUY922 in patients with advanced solid tumors
Clinical Cancer Research · 2013 · 134 citations
A study of donepezil in female breast cancer survivors with self-reported cognitive dysfunction 1 to 5 years following adjuvant chemotherapy
Journal of Cancer Survivorship · 2016 · 75 citations
Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma
British Journal of Cancer · 2017 · 62 citations

Zeina Nahleh
4 papers
Anthony Olszanski
2 papers
David Groteluschen
2 papers
ES
Edward Shaw
2 papers
Elizabeth Stone
2 papers
EB
Ernie Balcueva
2 papers
Geoffrey Shapiro
2 papers
Glenn Lesser
2 papers
Lainie Martin
2 papers
MK
Mark Kozloff
2 papers
Natasha Savage
2 papers · 1 as a fellow
RC
Roger Cohen
2 papers

Clinical trials

Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
Site PI · Recruiting
Tempus AI
2025–2033